Enhancing Cancer Treatment Decisions with Ultrasensitive MRD Testing

Quest Diagnostics, Jesus Izaguirre Carbonell, Thoman Slavin, MRD testing, minimal residual testing, precision tool, biomarker, ctDNA, circulating tumor DNA

Dr. Thomas Slavin breaks down how ultrasensitive MRD testing supports better cancer treatment decisions and enables earlier, more personalized interventions.

Jul 7^th • 19 mins listen

Tumor-Agnostic Therapies and the Future of HER2 in Oncology

Labcorp, Rebecca Previs, Heidi Ko, HER2, NGS, precision oncology, tumor agnostic, breast cancer, gastric cancer, biomarker, ERBB2, IHC, FISH, biomarker

What tumor-agnostic approvals mean for HER2, NGS, and precision oncology — and how they’re changing treatment across cancer types.

Jun 8^th • 20 mins listen